KRAS and lung carcinoma: For instance, transgenic mice over-expressing Myc shared many of the expression patterns observed in human prostate tumors having high MYC expression [22]; a mouse model of Kras2-mediated lung cancer shared expression patterns with human lung tumors harboring k-ras mutation [23]; and an SV40 T/t-antigen cancer gene signature activated in transgenic mouse tumors with aberrant p53, Rb, or BRCA1 expression was associated with poor prognosis in human breast, prostate, and lung carcinomas [24].